- News & Analysis
Page 157
Fortis fortifies with $40m
Existing backers Lilly Asia Ventures and Osage University Partners helped the UCSF cancer therapy spinout close its series A round.
Mar 31, 2021Fortis fortifies with $40m
Existing backers Lilly Asia Ventures and Osage University Partners helped the UCSF cancer therapy spinout close its series A round.
Mar 31, 2021Amgen rides to Rodeo acquisition
Amgen will pay an initial $55m and up to $666m in cash subject to milestones.
Mar 31, 2021Alydia exits to Organon
US-listed pharmaceuticals company Merck to spin off Organon after acquisition
Mar 31, 2021Lava breaks through to public markets
Lava Therapeutics, which is developing cancer treatments based on research at Amsterdam University Medical Centers, floated in a $101m offering.
Mar 30, 2021Cityblock collects $192m in series C extension
The Echo Health Ventures, Alphabet and EmblemHealth-backed care provider has secured about $500m in total, with the completion of a series C extension round.
Mar 30, 2021Akoya acts to file for $115m IPO
The Agilent Technologies-backed tissue analysis device maker has selected the Nasdaq Global Select Market for its initial public offering.
Mar 30, 2021Eli Lilly leads ImmuneOnco to $89m series C
Lilly Asia Ventures has returned to co-lead the cancer immunotherapy developer’s series C round with Greater Bay Area Homeland Investments.
Mar 30, 2021About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
© 2025 Mawsonia Ltd. All rights reserved.test regLogin